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Altered metabolism in cancer was first discovered by Otto Warburg early last century. Although the Warburg Effect has been 
widely used in tumor detection, relatively little progress had been made in mechanistic understanding of cancer metabolism in 
the subsequent eight decades. Genetic studies have recently identified mutations in human cancer targeting multiple enzymes 
involved in intermediate metabolism. One emerging mechanism common to these mutant enzymes is the accumulation of a 
metabolite that alters the epigenetic control.  
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Otto Warburg [1,2] first discovered that cancer cells dis-
played enhanced glucose uptake and aerobic glycolysis, a 
phenomenon often referred as the Warburg Effect nowadays. 
Although the mechanism underlying the Warburg Effect is 
still not fully understood, increased uptake of glucose pro-
vides the basis to exploit its clinical application by 
18F-deoxyglucose positron emission tomography (PET) for 
tumor detection [3,4]. Decades after the Warburg Effect was 
discovered, the mechanistic insights of how metabolic alter-
ations contribute to tumorigenesis are just emerging. Recent 
studies have revealed that eight metabolic genes, FH, SDHA, 
SDHB, SDHC, SDHD, SDHAF2, IDH1 and IDH2, encoding 
for subunits of four different metabolic enzymes, fumarate 
hydratase (FH), succinate dehydrogenase (SDH), and iso-
citrate dehydrogenase 1 and 2 (IDH1 and IDH2), were mu-
tated in a number of human cancers [5]. These findings pro-
vide compelling genetic evidence supporting the notion that 
altered metabolism contributes to, as opposed to the conse-
quence of, tumorigenesis. Here, we first briefly discuss how 
metabolism is reprogrammed to support cancer cell prolif-
eration. We then focus on one emerging mechanism that is 
common to the mutations targeting all four metabolic en-
zymes in accumulating a metabolite to alter the epigenetic 
modifications in human cancer.  
1  Cancer cells reprogram metabolism for pro-
liferation 
Cancer cells require much more energy, reductive power, 
and intermediates as precursors than normal cells for the 
biosynthesis of macromolecules to support the high rate of 
cell growth and proliferation. This was what Otto Warburg 
has observed more than 80 years ago as perhaps the first 
phenotype of tumor cells that they consume glucose at a 
surprisingly high rate compared with normal cells, and ac-
cumulate a significant amount of lactate rather than oxidiz-
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ing glucose completely to water and CO2 [1,2,6,7]. In other 
words, the tumor cells appear to favor the anaerobic metab-
olism even in the presence of normal oxygen supply.  
The high rate of glycolysis presumably provides several 
advantages for cell proliferation. First, increased glucose 
uptake allows cells to produce sufficient ATP. Because of 
the high rate of glycolytic activity, the percent of ATP pro-
duced from glycolysis could exceed that produced from 
oxidative phosphorylation [1]. Second and perhaps more 
importantly, glycolysis, as opposed to completely metabo-
lism of glucose to water and CO2 after TCA and oxidative 
phosphorylation, provides many intermediates for cell bio-
synthesis, including glycerol for lipids, ribose-5-phosphate 
for nucleotides, nonessential amino acids, and so on. Thus, 
high glucose uptake benefits the cancer cells both in bioen-
ergetics and biosynthesis.  
In addition to glucose, increased glutamine uptake is an-
other tumor-specific metabolic alteration [8,9]. Glutamine is 
first converted to glutamate by glutaminase and then deam-
inated to produce -ketoglutarate (α-KG) to enter the TCA 
cycle by either a transaminase or glutamate dehydrogenase. 
Glutamine plays several important roles in supporting cell 
growth and proliferation. First, glutamine serves as a carbon 
source and a nitrogen donor for energy production and bio-
synthesis. It was reported that glutamine could fully sustain 
the oxidative TCA cycle for energy production, even in the 
absence of glucose [10]. In proliferating cells, glutamine 
could contribute to citrate production and de novo lipogene-
sis through the reductive carboxylation of α-KG by iso-
citrate dehydrogenase under hypoxia and glucose starvation 
conditions [1013]. Second, glutamine serves as an activa-
tor of mTOR1, which is a central cell growth controller, to 
promote cell growth. Increased intracellular glutamine 
could be used to facilitate the import of essential amino ac-
ids [14,15]. Third, glutamine takes part in the synthesis of 
glutathione, an endogenous antioxidant, to maintain the 
cellular redox homeostasis. Stimulation of glutamine uptake 
by p53 was shown to result in an increased ratio of reduced 
to oxidized glutathione (GSH/GSSG) and protect the cells 
against oxidative stress [16,17]. 
2  Mutations of metabolic genes in cancer 
2.1  Mutations of SDH genes cause the accumulation of 
succinate 
Succinate dehydrogenase (SDH) is involved in the TCA 
cycle and also participates in the electron transport chain as 
the respiratory complex II. SDH is composed of four subu-
nits, which are named SDHA, SDHB, SDHC and SDHD, 
and is activated by SDH5 (also named SDHAF2) [18]. SDH 
catalyzes the conversion of succinate to fumarate with the 
concomitant reduction of ubiquinone to ubiquinol. The SDH 
gene was the first metabolic gene discovered to be mutated 
in human cancer, specifically in paragangliomas [19,20]. 
SDH mutations were also found in a number of other tumors, 
including gastrointestinal stromal tumors [21], renal cell 
tumors [22], childhood T-cell acute leukemia, pheochro-
mocytoma and neuroblastomas [23]. Among all the SDH 
mutations, a high frequency of SDH germline mutations 
was identified in malignant extra-adrenal paragangliomas, 
and these mutations were associated with poor prognosis 
[24–26]. These studies suggest that SDH mutations offer a 
strong advantage for cancer cell proliferation. So far, there 
have been more than 650 reported cases of SDH mutations. 
In three cases of paragangliomatosis (HPGL) with SDH 
mutation, succinate accumulated to a high level of 364–517 
μmol g1 protein [27]. More recently, it was reported that 
either depleting SDH in mice or ectopic expression of tu-
mor-derived SDH mutants resulted in the accumulation of 
succinate [28]. 
2.2  Mutations of FH genes in cancer cause the accu-
mulation of fumarate 
Fumarate hydratase (FH) is the enzyme next to SDH in the 
TCA cycle, and catalyzes the reversible hydration/dehydration 
of fumarate to malate. The human genome contains only 
one FH gene, which encodes two different forms of 
fumarate hydratase. The longer form localized in mitochon-
drion participates in the TCA cycle, and the short form lo-
calized in the cytoplasm is involved in the urea cycle and 
purine synthesis. Mutations in FH gene were first identified 
in inherited uterine fibroids, skin leiomyoma and papillary 
renal cell cancer by a combination of mapping methods [29]. 
FH mutations were also found in cerebral cavernomas [30], 
Leydig cell tumors [31] and ovarian mucinous cystadenoma 
with low frequency [32]. So far, FH mutations have been 
found in more than 300 cases. As with SDH mutations, FH 
mutations resulted in the accumulation of fumarate to a level 
as high as 417–688 mol/g protein in hereditary leiomy-
omatosis and renal cell cancer [27]. The accumulation of 
fumarate was also observed in cells depleted for FH or ex-
pressing a tumor-derived FH mutant [28].  
2.3  IDH1 and IDH2 are most frequently mutated 
metabolic genes in human cancers 
IDH catalyzes the oxidative decarboxylation of isocitrate to 
produce -KG. The IDH family includes three different 
isoforms: IDH1, IDH2 and IDH3. IDH1 is located in the 
cytosol and peroxisomes, while IDH2 and IDH3 are located 
in mitochondria. IDH1 and IDH2 use NADP+ as a cofactor, 
while IDH3 uses NAD+ as a cofactor in the TCA cycle for 
energy metabolism [33].  
The IDH1 mutation was first found in human glioblas-
toma multiforme by a cancer genome project in 2008 [34]. 
A short time later, another cancer genome project identified 
a mutation in the IDH1 gene in leukemic cells from an acute 
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myeloid leukemia (AML) patient compared with his normal 
skin cells [35]. These two findings were quickly confirmed 
by multiple groups through direct sequencing of IDH1 and 
its homologue IDH2. Mutations in IDH1 and IDH2 were 
found in 75% of grade 2 to 3 gliomas and secondary glio-
blastoma, and in about 20% of AML [36–48]. Following the 
discovery in glioma and AML, IDH1 and IDH2 mutations 
were also found in several other human tumors, including 
cartilaginous tumors (75%) [49–51], intrahepatic cholangio-
carcinoma (10%) [52,53], thyroid carcinomas (16%) [54,55], 
and less frequently in prostate cancer, acute B-lymphoblastic 
leukemia, paragangliomas, colorectal carcinoma, and mela- 
noma [52,56,57]. Thus, IDH1 and IDH2 represent the  
most frequently mutated metabolic genes in human cancer 
(Table 1). 
The mutations of IDH1 and IDH2 in different types of 
human tumors share four unique biochemical features. First, 
IDH1 and IDH2 mutations are all heterozygous and there is 
no loss of heterozygosis of the wild-type copy. This is con-
sistent with both a gain of function and dominant effect over 
the remaining wild-type allele. Second, nearly all IDH1 and 
IDH2 mutations predominantly target a single amino acid 
residue, Arg132 in IDH1 (to one of six amino acid residues: 
His, Cys, Leu, Ile, Ser, Gly, or Val), or the corresponding 
Arg172 in IDH2 (to one of four different residues: Lys, Met, 
Gly, and Trp), and Arg140 in IDH2 (to either Gln or Trp). 
Moreover, these three residues are located in the active sites 
of the enzymes, suggesting a direct impact of the mutations 
on the enzyme catalytic activity. Two additional mutations 
targeting IDH1, R100A and G98D, was also found to occur 
less frequently in adult glioma and in a colon cancer cell 
line [58]. Third, all IDH1 and IDH2 mutations in human 
tumors are found to be somatic mutations, with germline 
mutations rarely observed. Finally, IDH1 and IDH2 muta-
tions occur in a mutually exclusive manner in most cases, 
and few tumors have been found to harbor mutations in both 
IDH1 and IDH2 genes [38]. This fact suggests that muta-
tions targeting IDH1 and IDH2 share a common underlying 
biochemical mechanism.  
2.4  Mutant IDH1 and IDH2 lose their normal activity 
to produce -KG and gain a new activity of producing 
D-2-HG 
Shortly after the first IDH1 mutation was reported, it was 
found that tumor-derived IDH1 mutants lost their normal 
activity to produce -KG. This functional inactivation led to 
a decrease of -KG and increase of HIF1a protein levels, 
possibly because of the inhibition of prolyl hydroxylase 
(PHD) [59]. Thus, loss of the normal function of producing 
-KG is the first biochemical alteration of tumor-derived 
IDH1 and IDH2 mutants.  
A subsequent study using metabolite profiling surpris-
ingly found that the IDH1 mutant not only loses its normal 
activity in the production of -KG, but also gains a new 
function: catalyzing the NADPH-dependent reduction of 
-KG to D-2-hydroxyglutarate (D-2-HG, also known as 
R-2-HG) [60]. Further studies showed that all the tu-
mor-derived mutants targeting three hot spots, Arg132 in 
IDH1 and Arg140 and Arg172 in IDH2, also gain this new 
activity [61–63]. In human glioma with IDH1/2 mutation, the 
level of D-2-HG accumulates as high as 5–35 mol g1 (or 
5–35 mmol L1) [42]. In addition to glioma, D-2-HG accu-
mulation has also been found in AML and enchondroma 
[50]. Taking advantage of such high D-2-HG levels, efforts  
Table 1  Mutation of eight metabolic genes 















Prostate cancers 2/79 
B-cell ALL 1/60 
Paragangliomas 1/131 







SDHB Merkel cell carcinoma 2/18 
SDHC Phaeochromocytoma 5/22 
SDHD GIST 6/38 




Rebal cell carcinoma 1/3 
Lung adenocaicinoma 1.1% 
Melanoma 1/14 
Leiomyoma 1.3% 
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have been made to noninvasively detect the accumulation of 
D-2-HG in glioma patients by magnetic resonance spec-
troscopy techniques for tumor diagnosis and imaging [64, 
65].  
3  The mechanism of tumorigenesis linked to 
SDH, FH and IDH mutations 
3.1  -KG dependent dioxygenases are a large family of 
enzymes involved in diverse cellular processes 
One emerging mechanism common to the tumorigenesis 
linked to mutations in all four metabolic enzymes is that 
they all lead to impaired activity of a family of enzymes 
collectively known as -KG-dependent dioxygenases. In 
1967, Hutton et al. [66] identified the first -KG-dependent 
dioxygenase, which was named collagen prolyl hydroxylase 
(CPH). After this pioneering work, the -KG-dependent 
dioxygenases have been established as a widely distributed 
family. Sequence homology analysis suggests that there are 
more than 60 members in humans [67,68]. The -KG de-
pendent dioxygenases catalyze the hydroxylation reactions 
with diverse substrates, including collagen, histones, tran-
scription factors, alkylated DNA and RNA, lipids, antibiotics, 
and the recently discovered 5-methylcytosine of genomic 
DNA and 6-methyladenine of RNA [69,70]. In recent years, 
the biological roles of -KG-dependent dioxygenases have 
been expanded to multiple pathways, such as CPHs in col-
lagen stabilization and endostatin production, trimethyl-
lysine hydroxylase in fatty acid metabolism, prolyl hydrox-
ylases (PHDs) and factor inhibiting-HIF (FIH) in hypoxic 
signaling, AlkB homologs in DNA and RNA repair, histone 
lysine demethylases (KDMs) and DNA hydroxylases of 
ten-eleven translocases (TETs) for epigenetic regulation on 
histones and DNA (Table 2). 
-KG plays critical roles in multiple cellular metabolic 
pathways, such as TCA cycle, anaplerosis, amino acid and 
fatty acid synthesis, and hydroxylation of proteins and nu-
cleic acids. In the hydroxylation reaction, -KG serves as a 
co-substrate for all -KG-dependent dioxygenases [70], 
which use both atoms of molecular oxygen for substrate 
hydroxylation. Both -KG and O2 are considered to be 
cosubstrates, with one oxygen atom attached to a hydroxyl 
group in the substrate (hydroxylation) and the other one 
taken up by -KG, leading to the decarboxylation of -KG 
and formation of carbon dioxide and succinate. All -KG- 
dependent dioxygenases require Fe(II) as a cofactor. The 
last role of -KG in supporting the -KG-dependent diox-
ygenases appear to be impaired in cells with mutation tar-
geting any of four metabolic enzymes.  
3.2  SDH and FH mutants inhibit multiple -KG de-
pendent dioxygenases 
In 1977, Raili et al. [71] found that succinate was a compet-
itive inhibitor of -KG and could suppress CPH, an -KG 
dependent dioxygenase involved in collagen biosynthesis. 
Several years after the SDH mutation was reported, it was 
shown that the elevated level of succinate in cells caused by 
the inhibition of SDH could lead to the inhibition of PHDs, 
resulting in accumulation of both HIF-1 and HIF-2 [27]. 
This unveiled the first biochemical mechanism linking suc-
cinate to tumorigenesis. Another study further provided in 
vivo evidence for this model. Elevated levels of succinate 
and fumarate caused by SDH mutations in paragangliomas 
and FH mutations in renal cell cancer, respectively, lead to 
the accumulation of HIF-1α through the inhibition of PHD 
[27]. As expected, elevated HIF-1 is also observed in cells  
Table 2  -KG dependent dioxygenases and their substrates 
Dioxygenase Km for KG  Substrate Effect on substrate Associated disease 
CPH-I (collagen prolyl hydroxylase, type I) 22 mol L1  Collagen Stabilization Scurvy 
CPH-II (collagen prolyl hydroxylase, tyep II) 22 mol L1  Collagen Stabilization Scurvy 
PHD1 (proline hydroxylase domain protein 1) 60 mol L1  HIF-2 Degradation ? 
PHD2 (proline hydroxylase domain protein 2) 60 mol L1  HIF-1 Degradation Cancer 
PHD3 (proline hydroxylase domain protein 3) 60 mol L1  HIF-2 Degradation ? 




















  NFB ? ? 
  Notch receptor ?  
  ASB4 ?  
PhyH (phytanoyl coenzyme A hydroxylase) ? phytanoyl coenzyme A  Refsum disease 
FTO (fat mass and obesity associated) ? DNA demethylation  Obesity 
ABH1-8 (AlkB homologs) ?  DNA (and RNA?) demethylation  DNA repair 
AlkB (E. coli) 1 mol L1  DNA demethylation   
KDM/JMJD (JmiC domain proteins) ? 
 
Histone demethylation  
Gene regulation 
epigenetics 
TET (Ten Eleven-translocation) ? 
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with mutations of SDH or FH.  
The KDMs and TET DNA hydroxylases are two 
sub-families of -KG-dependent dioxygenases that control 
the epigenetic modifications in the cells. A recent study 
showed that both succinate and fumarate inhibit KDM from 
human and C. elegans. The IC50 of succinate and fumarate 
of human KDM4A are 0.8 and 1.5 mmol L1, respectively 
[28]. Knocking down SDH or FH or overexpression of the 
tumor-derived SDH or FH mutant significantly increased 
genome-wide histone and DNA methylation [28]. Further-
more, two DNA methylation profiling studies found that 
SDH mutations in gastrointestinal stromal tumors, paragan-
gliomas and pheochromocytomas were associated with ge-
nomic hypermethylation [72,73]. In addition, decreased 
levels of 5-hydroxymethylcytosine were associated with 
SDH mutations in gastrointestinal stromal tumors [74]. 
Taken together, the in vivo evidence strongly supports that 
mutation in FH or SDH results in global genome changes in 
DNA methylation, likely due to inhibition of TET proteins 
by fumarate or succinate, thus leading to epigenetic altera-
tions in cancers. These studies raise an exciting possibility 
of treating cancers by interfering with epigenetic pathways. 
3.3  IDH mutants inhibit -KG-dependent histone and 
DNA demethylases 
The oncometabolite of D-2-HG, produced by IDH mutants, 
acts as an antagonist of -KG to inhibit multiple -KG de-
pendent dioxygenases. However, not all -KG dependent 
dioxygenases are equally inhibited by D-2-HG. A system-
atic in vitro enzymatic study showed that the histone 
H3K9/H3K36 demethylases KDM4A/JMJD2A and KDM4C/ 
JMJD4C are most sensitive to a low IC50
 of 24 and 79 mol 
L1, respectively [75]. Three in vivo studies confirmed this 
finding in cultured cells, human tumor samples, and mouse 
models. First, elevated levels of multiple histone methyla-
tion markers were observed in cells expressing tumor-     
derived IDH1/2 mutants and gliomas with an IDH1R132H 
mutation [63]. Second, IDH mutation is associated with a 
block to differentiation and repression of lineage-specific 
differentiation genes through the inhibition of KDM4C [76]. 
Third, increased levels of histone methylation markers, in-
cluding trimethyl H3K4, H3K9, H3K27, and H3K36 and 
dimethyl H3K79, are observed in IDH1R132H knock-in cells 
[77] and an IDH1R132H conditional knock-in mouse model 
[78].  
The TET family of DNA hydroxylases catalyzes three 
sequential oxidative reactions, first converting 5-methyl-   
cytosine (5mC) to 5-hydroxylcytosine (5hmC), then to 
5-formaylcytosine (5fC), and finally to 5-carboxylcytosine 
(5caC), leading to DNA demethylation [79–83]. D-2-HG 
directly inhibits TET activity in vitro, and the expression of 
tumor-derived IDH1 or IDH2 mutants also inhibits TET-    
induced 5mC hydroxylation in transfected cells [61,63]. 
Importantly, genetic evidence supports TET DNA hydrox-
ylase as the major target of IDH1/2 mutations. First, a pro-
moter methylation analysis study demonstrated that a subset 
of glioblastoma, a proneural subgroup that is tightly associated 
with IDH1 mutations, shows a distinct CpG island methyla-
tion phenotype (G-CIMP) [84]. A similar DNA hypermethyl-
ation phenotype is observed in AML with IDH1/2 mutation 
[61]. Recently, two genetic models, IDH1(R132H/WT) 
knock-in cells and mice, also showed global DNA hyper-
methylation [77,78]. These findings suggest a causal link 
between IDH1/2 mutation and elevated DNA methylation. 
Second, mutations of TET2 occur in a mutually exclusive 
manner with IDH1/2 mutations, indicating a common path-
ogenesis caused by mutation in TET2 or IDH1/2 in AML 
[61]. Third, stable expression of an IDH1 mutant in primary 
human astrocytes induces extensive DNA hypermethylation 
and reshapes the methylome in a fashion that mirrors the 
changes observed in G-CIMP-positive lower-grade gliomas 
that have frequent IDH mutations [85]. Collectively, these 
studies establish a model in which TET hydroxylases are 
the major targets of IDH1/2 mutations to promote tumor-
igenesis.    
3.4  Succinate, fumarate and D-2-HG are structurally 
similar to and act as antagonists of -KG 
Structural studies have revealed a conserved coordination 
between -KG-dependent dioxygenases and their cofactor 
and cosubstrate. In the catalytic core of -KG-dependent 
dioxygenases, -KG uses two oxygen atoms from the 
-keto carboxyl end, one from its C-1 hydroxyl group and 
the other from its C-2 ketone group, to coordinate with 
Fe(II), and two other oxygen atoms from the acetate end to 
interact with conserved amino residues in the dioxygenases. 
Structural analysis shows that D-2-HG is similar to -KG 
except for the oxidative state at the C-2, whereby the ketone 
group is replaced by a hydroxyl group in D-2-HG (Figure 1). 
Likewise, both succinate and fumarate are structurally sim-
ilar to -KG, with the exception that the ketone group at the 
C-2 position in -KG is missing in succinate and fumarate 
(Figure 1). Thus, these structural similarities suggest that 
succinate, fumarate and D-2-HG may act as competitive 
inhibitors of -KG to interfere with the function of 
-KG-dependent dioxygenases. This hypothesis was sup-
ported by a series of experiments both in vitro and in vivo 
[27,63,71–74,84]. Moreover, structural analyses have 
shown that succinate and fumarate could bind the -KG-    
dependent dioxygenases in their catalytic core just like 
-KG, such as FIH and AlkB [70,86]. Additionally, 
D-2-HG binds KDM7A in a configuration similar to -KG 
[63]. Thus, these results provide direct evidence supporting 
succinate, fumarate, and D-2-HG as antagonists of α-KG in 
the cell to inhibit α-KG-dependent dioxygenases.  
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4  Conclusion and perspectives 
During the past ten years, researchers have shown increas-
ing interest in metabolism alterations in tumorigenesis, 
fueled in part by the discovery of metabolic gene mutations 
in cancer. Common metabolites not only can regulate en-
zyme activity through classical allosteric effects, but also 
influence multiple cellular processes through global effects, 
such as inhibition of the dioxygenase family. As discussed 
above, three oncometabolites, D-2-HG, succinate and 
fumarate, act as antagonists of -KG and inhibit a large 
number of -KG-dependent dioxygenases to control a di-
versity of cellular activities, including hypoxia response and  
epigenetics regulation (Figure 2). One may also speculate 
that many other metabolites serve as signaling molecules to 
influence whole cell and body physiology. Therefore, pro-
teins/enzymes that are regulated by metabolites can be con-
sidered as cellular sensors for metabolic status, thereby 
functioning to coordinate global cellular activity/function 
with metabolic status.  
The realization that metabolites can have global regula-
tory effects on cells not only significantly advances our un-
derstanding of the intricate regulatory network between 
small molecules (metabolites) and macromolecules (protein, 
RNA, and DNA), but also provides exciting leads for future 
therapeutic intervention for disease treatments. By nature, 
small molecules are much easier to be produced, optimized  
 
 
Figure 1  Structural comparison of fumarate, succinate, -KG, and D-2-HG. The oxygen in the ketone group at the C-2 position of -KG is responsible for 
the coordination of Fe(II) in α-KG-dependent dioxygenase. All three oncometabolites, D-2-HG, fumarate and succinate, share structural similarity with 
-KG, except for the oxidative state at the C-2 position. The 2-ketone group at the C-2 position in -KG is replaced by a hydroxyl group in D-2-HG and is 
absent in fumarate and succinate. 
 
Figure 2  IDH1/2 mutations alter epigenetic regulation by inhibiting both histone and DNA demethylation. Mutations of IDH1/2, SDH and FH lead to the 
accumulation of D-2-HG, fumarate and succinate, respectively, which can function as -KG antagonists to broadly inhibit -KG-dependent dioxygenases, 
including the JMJD family KDMs and the TET family of 5mC hydroxylases. PGL, paragangliomatosis; AML, acute myeloid leukemia; RCC, renal cell 
carcinoma.  
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by modification, and delivered into the human body. The 
mechanistic understanding of metabolites in cellular regula-
tion will facilitate the use of metabolites or their analogs for 
treatment of human disease. 
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